Danske Bank A S Takes $37.33 Million Position in Elevance Health, Inc. $ELV

Danske Bank A S purchased a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 115,518 shares of the company’s stock, valued at approximately $37,326,000. Danske Bank A S owned approximately 0.05% of Elevance Health at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Mizuho Markets Cayman LP bought a new position in shares of Elevance Health in the 3rd quarter valued at $7,829,000. Advisory Services Network LLC lifted its position in shares of Elevance Health by 67.7% during the 3rd quarter. Advisory Services Network LLC now owns 6,427 shares of the company’s stock worth $2,077,000 after buying an additional 2,594 shares during the last quarter. Integrated Investment Consultants LLC boosted its stake in Elevance Health by 13.9% in the third quarter. Integrated Investment Consultants LLC now owns 1,187 shares of the company’s stock valued at $384,000 after buying an additional 145 shares in the last quarter. Hancock Whitney Corp boosted its stake in Elevance Health by 15.8% in the third quarter. Hancock Whitney Corp now owns 7,997 shares of the company’s stock valued at $2,584,000 after buying an additional 1,092 shares in the last quarter. Finally, OmniStar Financial Group Inc. bought a new position in Elevance Health in the third quarter valued at about $513,000. 89.24% of the stock is owned by institutional investors.

Elevance Health Trading Down 0.3%

NYSE:ELV opened at $294.98 on Thursday. The firm’s fifty day moving average is $333.87 and its 200-day moving average is $333.89. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The firm has a market cap of $65.10 billion, a P/E ratio of 11.74, a P/E/G ratio of 1.62 and a beta of 0.51.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a $1.72 dividend. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.3%. Elevance Health’s dividend payout ratio is 27.39%.

Analyst Ratings Changes

A number of research analysts have recently commented on ELV shares. TD Cowen reissued a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Truist Financial lowered their price objective on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Weiss Ratings downgraded shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Finally, Mizuho cut their target price on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Twelve analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.